- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04683900
Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease a Randomized, Controlled, Clinical Trial (MEDI-PD)
Mediterranean Diet Intervention to Improve Gastrointestinal Function in Parkinson's Disease: a Randomized, Controlled, Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32611
- University of Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Physician-diagnosed Parkinson's disease aged 40-85 years
- Drug naïve or on stable dosage of Parkinson's medications with no plans to change for the duration of the study protocol
- Hoehn & Yahr stage =<2.5 in the clinical "ON" state
- Constipation syndrome scores >=2.0 based on the GSRS
- Consume <20 grams of fiber daily based on the Block Fruit/Vegetable/Fiber screener
- Able to complete informed consent in English
- Willing to maintain habitual diet through the pre-baseline period.
- Willing to make dietary changes to follow a Mediterranean diet and/or receive standard of care for constipation during the intervention period.
- Willing to complete daily and weekly questionnaires and 12 dietary recalls over approximately 10 weeks.
- Able to provide stool samples during the study collection periods.
- Willing to avoid strenuous exercise and alcohol such as beer, wine, and cocktails 24 hours prior to each of the 3 study visits.
- Able to fast (no food or drink, except water, or decaf tea) at least 12 hours before each study visit
- Willing to discontinue taking prebiotic, herbal, or high-dose vitamin or mineral supplements that may impact inflammation during the pre-baseline period and throughout the study protocol.
Exclusion Criteria:
- Atypical or secondary Parkinsonism
- Underweight (BMI <18.5)
- History of deep brain stimulation (DBS) surgery
- Regular use of enemas or suppositories to alleviate constipation (e.g., >1 time per week)
- Use of another investigational product within 3 months of the screening visit
- Antibiotic or probiotic supplement use within 2 months from the day of stool collection
- Currently being treated for a physician-diagnosed GI disease or condition other than constipation, irritable bowel disease, gastroparesis, reflux or diverticular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Standard of Care + Mediterranean Diet
Participants will be given standard of care for constipation (handout) plus individualized diet education on the Mediterranean diet and instructed to follow the diet during the 8-week intervention period.
Diet education will be administered by a study dietitian and followed with weekly phone calls to ensure compliance, improve adherence to the diet and monitor for adverse events.
|
Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic. The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake. Laxative medications and recommendations for usage are included. Participants will be instructed to include the following in their diet: a) abundant use of olive oil for cooking and dressing dishes; b) consume ≥2 daily servings of vegetables; c) ≥2-3 daily serving of fruits; d) ≥3 weekly servings of legumes; e) ≥3 weekly servings of fish/seafood; f) ≥3 weekly serving of nuts/seeds; g) select white instead of red or processed meats; h) cook at least twice a week with sofrito. Limit consumption of cream, butter, processed meat, sugared beverages, industrial bakery products and desserts, and French fries or chips. For usual drinkers, the main source of alcohol should be wine. |
ACTIVE_COMPARATOR: Standard of Care
Participants will be given standard of care for constipation (handout) to utilize during the 8-week intervention period.
A study dietitian will follow up with weekly phone calls to support adherence and monitor for adverse events.
|
Participants will receive a constipation management handout that is distributed regularly to patients who present with constipation symptoms at an outpatient neurology clinic.
The handout recommends increasing fluids daily, as well as increasing physical activity and dietary fiber intake.
Laxative medications and recommendations for usage are included.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
GSRS Constipation Syndrome Score
Time Frame: 10 weeks
|
The difference between mean change (final - baseline) in constipation syndrome scores for the Med diet versus control diet.
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Stool Frequency
Time Frame: Each week up to 10 weeks
|
Compare the number of stools between the intervention and control groups
|
Each week up to 10 weeks
|
Stool Form
Time Frame: Each day up to 10 weeks
|
Compare stool form, as measured by the Bristol Stool Form Scale (BSFS), between the intervention and control groups.
The BSFS is scored between 1 (hard stool) - 7 (liquid stool).
|
Each day up to 10 weeks
|
Laxative Usage
Time Frame: Each week up to 10 weeks
|
Compare number of days using laxative medications between the intervention and control groups.
|
Each week up to 10 weeks
|
Digestive Health
Time Frame: Every week up to 10 weeks
|
Weekly GI symptoms assessed using the Gastrointestinal Symptom Rating Scale (GSRS).
The GSRS consists of 15 questions related to 5 syndromes, constipation, diarrhea, reflux, abdominal pain, and indigestion.
Symptoms are scored 1=no discomfort to 7=very severe discomfort.
Scores from each of the 15 questions are summed for the total GSRS score.
|
Every week up to 10 weeks
|
Quality of Life Related to Digestive Health
Time Frame: Every week up to 10 weeks
|
Weekly GI experiences assessed using an in-house Digestion-Associated Quality of Life questionnaire.
|
Every week up to 10 weeks
|
Fecal Microbial Diversity
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in fecal microbial composition and diversity (i.e.
alpha and beta diversity) will be assessed.
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Fecal Microbial Quantitative Polymerase Chain Reaction (qPCR)
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in fecal microbial composition to quantify bacterial species of interest (e.g., F. prausnitzii, Prevotella, Roseburia, Bilophila, Akkermansia, etc.) will be assessed.
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Intestinal Inflammation and Permeability
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in fecal calprotectin and zonulin will be assessed using enzyme-linked immunosorbent assay
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mediterranean diet adherence
Time Frame: Each week up to 10 weeks
|
Compare Mediterranean diet adherence scores using the 14-Item Mediterranean diet adherence screener (MEDAS) between groups
|
Each week up to 10 weeks
|
Dietary Fiber Intake
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in dietary fiber intake as measured by averaged 4-day dietary recalls using the Automated Self-Administered 24-hour dietary recall (ASA-24) between groups
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Body weight
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in body weight between groups
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Body Composition (Fat Free Mass)
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in fat free mass using bio-impedance spectroscopy (BIS) between groups
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Handgrip strength
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in handgrip strength will be assessed using a hand dynamometer between groups
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Quality of Life (QOL)
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in QOL will be assessed using the Parkinson's Disease Quality of life -39 (PDQ-39)
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Anxiety
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in symptoms of anxiety will be assessed using the Hamilton Anxiety Rating Scale
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Depression
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in symptoms of anxiety will be assessed using the Hamilton Depression Rating Scale
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Physical Activity
Time Frame: Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Changes in MET minutes will be assessed using the International Physical Activity Questionnaire (IPAQ).
|
Baseline (Week 0); Midpoint (Week 4); Final (Week 8)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB202001333
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Standard of care + Mediterranean diet (intervention)
-
Harokopio UniversityNational and Kapodistrian University of AthensCompleted
-
Universidade Nova de LisboaHospital de Santa Marta - Centro Hospitalar Universitário, Lisboa Central...Not yet recruitingAcute Myocardial Infarction With ST Elevation
-
Basque Culinary Center FundazioaUniversity of NavarraCompletedObesity | Cognitive Impairment | Healthy AgingSpain
-
Basque Culinary Center FundazioaUniversity of NavarraCompletedType 2 Diabetes MellitusSpain
-
Stanford UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingObesity | Diabetes Mellitus, Type 2 | Insulin Resistance | PreDiabetes | Diet Modification | Nonalcoholic Steatohepatitis | Nonalcoholic Fatty LiverUnited States
-
Harvard School of Public Health (HSPH)Tufts University; National Institute for Public Safety Health, Indianapolis; U...CompletedHealth Behavior | Program Sustainability | Diet, Mediterranean | Program EffectivenessUnited States
-
Queen's University, BelfastUniversity College Dublin; Wageningen University; Dublin City University; Friedrich-Alexander-Universität...RecruitingCognitive Impairment | Cognitive Decline | Poor NutritionUnited Kingdom
-
Acibadem UniversityCompletedHashimoto Disease | Hashimoto ThyroiditisTurkey
-
University of JaenCompleted
-
Federico II UniversityRecruitingObesity | Birth Weight | Breast Feeding | Gestational Weight Gain | Allergies | Chronic Diseases in Children | Gestational Complications | Perinatal ConditionItaly